Article Figures & Data
Figures
- Figure 1. Immune cell populations are altered in the peripheral blood of patients with ALS
(A) The total number of leukocytes and (B) the percent and total number of specific leukocyte populations are shown. Filled black circles represent individual healthy human control patients, and empty circles represent patients with ALS. Average and SEM are displayed. Asterisks above bars indicate significance (% of CD45+ cells: *p < 0.01, ***p < 0.0001; # of leukocytes: *p < 0.008). ALS = amyotrophic lateral sclerosis.
- Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression
The percentage and total number of leukocytes in the blood of patients with amyotrophic lateral sclerosis are correlated with their ALSFRS-R score at the time of blood draw. Data are displayed with best-fit line and 95% confidence intervals. R2 value and p value are also shown. ALSFRS-R scores are displayed from high (A) to low (B) to illustrate disease progression. ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised.
- Figure 3. Percentage and total number of CD16− monocytes expressing CCR3 is reduced in patients with ALS
The percentage and total number of CD16+ and CD16− monocytes expressing CCRL2 (A) and CCR3 (B) in the peripheral blood are shown. Filled black circles represent individual healthy human control patients, and empty circles represent patients with ALS. Average and SEM are displayed. Asterisks above bars indicate significance (*p < 0.025). ALS = amyotrophic lateral sclerosis.
- Figure 4. The N:M ratio is significantly increased in patients with ALS and correlates with disease progression
(A) The N:M ratio in healthy control patients (filled black circles) and patients with ALS (empty circles) is shown. Average and SEM are displayed. Asterisks above bars indicate significance (***p < 0.001). (B) The N:M ratio in the blood of patients with ALS is correlated with the ALSFRS-R score at the time of blood draw. Data are displayed with best-fit line and 95% confidence intervals. R2 value and p value are also shown. ALSFRS-R scores are displayed from high (left) to low (right) to illustrate disease progression. ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating Scale–Revised; N:M ratio = neutrophil to CD16− monocyte ratio.
Tables
Data Supplement
Files in this Data Supplement:
- Data Supplement - PDF
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.